Payment overview · 2025
General Payments
$29,088.04
138 reported records · 30 companies
Healthcare provider profile · identity verified
George Katsamakis, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LAKE BARRINGTON, IL · NPI 1174502835
Verified facts
What the public records show
CMS Open Payments records show George Katsamakis, M.D. received $29,088.04 in general payments during 2025 across 138 reported records.
TG Therapeutics, Inc. accounted for 73.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Tecfidera by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mayzent by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21,436.03 | 73.7% | 23 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $5,439.73 | 18.7% | 18 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $288.58 | 1.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $278.03 | 1.0% | 24 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $173.87 | 0.6% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $138.89 | 0.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $127.08 | 0.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.85 | 0.3% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $98.52 | 0.3% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $96.56 | 0.3% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $93.74 | 0.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.17 | 0.3% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $89.08 | 0.3% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $85.31 | 0.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.24 | 0.2% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $61.71 | 0.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $51.99 | 0.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.33 | 0.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.95 | 0.2% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $45.36 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.41 | 0.1% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.70 | 0.1% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $25.20 | 0.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.17 | 0.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.59 | 0.1% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.28 | 0.1% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.92 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17.87 | 0.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.42 | 0.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.46 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,407.50 | 7 |
| Consulting Fee | $5,050.00 | 1 |
| Food and Beverage | $3,348.56 | 128 |
| Travel and Lodging | $281.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $21,436.03 | 23 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $5,439.73 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $253.84 | 20 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $215.58 | 21 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $138.89 | 5 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $138.89 | 5 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $127.08 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $107.08 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $101.85 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $98.52 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $93.74 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $93.57 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $92.17 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $89.08 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $85.31 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $68.24 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $57.63 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $54.22 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $51.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.33 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $46.95 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $45.36 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $42.34 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $36.20 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Patient Interface Software Normalized: patient interface software |
Device | Philips North America LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Baclofen | Baclofen | 280 | 79 |
| Gabapentin | Gabapentin | 255 | 66 |
| Dalfampridine Er | Dalfampridine | 224 | 32 |
| Pregabalin | Pregabalin | 95 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 73 | 20 |
| Levetiracetam | Levetiracetam | 62 | 19 |
| Alprazolam | Alprazolam | 61 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 13 |
| Clonazepam | Clonazepam | 60 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 16 |
| Topiramate | Topiramate | 57 | 16 |
| Kesimpta Pen | Ofatumumab | 56 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 15 |
| Modafinil | Modafinil | 48 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 43 | 13 |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Diazepam | Diazepam | 37 | suppressed |
| Teriflunomide | Teriflunomide | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 28 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Tecfidera | Dimethyl Fumarate | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Mayzent | Siponimod | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Neurontin | Gabapentin | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29,088.04 · 138 records | TG Therapeutics, Inc. | AMPYRA, AMYVID, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, Briviact, FIRDAPSE, GOMEKLI, Gocovri, HYQVIA, INBRIJA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Ocrevus, Ocrevus Zunovo, Patient Interface Software, QULIPTA, Qelbree, Radicava, Rystiggo, Sunosi, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA, ZTLido | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error